These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 24607445

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB, Weinstock M.
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [Abstract] [Full Text] [Related]

  • 3. [Monoamine oxidase as a target for drug action].
    Drozak J, Kozłowski M.
    Postepy Hig Med Dosw (Online); 2006 Jan; 60():498-515. PubMed ID: 17060892
    [Abstract] [Full Text] [Related]

  • 4. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB, Fridkin M, Zheng H.
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [Abstract] [Full Text] [Related]

  • 5. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.
    Youdim MB, Riederer P.
    J Neural Transm Gen Sect; 1993 Feb; 91(2-3):181-95. PubMed ID: 8390270
    [Abstract] [Full Text] [Related]

  • 6. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S, Zheng H, Fridkin M, Youdim MB.
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [Abstract] [Full Text] [Related]

  • 7. Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice.
    Villarinho JG, Fachinetto R, de Vargas Pinheiro F, da Silva Sant'Anna G, Machado P, Dombrowski PA, da Cunha C, de Almeida Cabrini D, Pinto Martins MA, Gauze Bonacorso H, Zanatta N, Antonello Rubin M, Ferreira J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct 01; 39(1):31-9. PubMed ID: 22525823
    [Abstract] [Full Text] [Related]

  • 8. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ, Swope DM, Dashtipour K.
    Clin Ther; 2007 Sep 01; 29(9):1825-49. PubMed ID: 18035186
    [Abstract] [Full Text] [Related]

  • 9. [Inhibitory monoamine oxidases of the new generation].
    Nowakowska E, Chodera A.
    Pol Merkur Lekarski; 1997 Jul 01; 3(13):1-4. PubMed ID: 9432289
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
    Kitaichi Y, Inoue T, Nakagawa S, Izumi T, Koyama T.
    Eur J Pharmacol; 2006 Feb 27; 532(3):236-45. PubMed ID: 16487506
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamine.
    Kitaichi Y, Inoue T, Nakagawa S, Boku S, Izumi T, Koyama T.
    Eur J Pharmacol; 2010 Jul 10; 637(1-3):77-82. PubMed ID: 20406628
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
    Szökő É, Tábi T, Riederer P, Vécsei L, Magyar K.
    J Neural Transm (Vienna); 2018 Nov 10; 125(11):1735-1749. PubMed ID: 29417334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.